HER2 mutant non-small cell lung cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:12 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png HER2 mutant non-small cell lung cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-with-pembrolizumab-versus-platinum-chemotherapy-with-pembrolizumab-for-patients-with-untreated-her2-positive-non-small-cell-lung-cancer/ Thu, 30 Apr 2026 13:08:07 +0000 https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-with-pembrolizumab-versus-platinum-chemotherapy-with-pembrolizumab-for-patients-with-untreated-her2-positive-non-small-cell-lung-cancer/ This study focuses on treating people with Non-small Cell Lung Cancer that has spread to other parts of the body or cannot be removed by surgery. Specifically, it involves patients whose cancer cells show high levels of a protein called HER2. The study will test a combination of two medications: trastuzumab deruxtecan (also known as DS-8201a) with pembrolizumab, comparing it to standard treatment that combines platinum-based chemotherapy (either cisplatin or carboplatin) with pembrolizumab.

The purpose of this research is to determine if the combination of trastuzumab deruxtecan with pembrolizumab works better than the standard treatment in controlling the disease. The medications will be given through an intravenous infusion, which means they are delivered directly into a vein. Trastuzumab deruxtecan is a type of medication that specifically targets cancer cells with high HER2 levels, while pembrolizumab helps the body’s immune system fight cancer cells.

During the study, participants will be randomly assigned to receive either the new combination treatment or the standard treatment. Their cancer will be monitored regularly using imaging scans to check how well the treatment is working. The doctors will continue to check the participants’ health and watch for any side effects throughout the study period.

]]> Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer https://clinicaltrials.eu/trial/study-of-zanidatamab-in-adults-with-her2-positive-solid-tumors-including-endometrial-colorectal-head-and-neck-cancers-sarcoma-or-her2-mutant-non-small-cell-lung-cancer/ Thu, 30 Apr 2026 13:07:57 +0000 https://clinicaltrials.eu/trial/study-of-zanidatamab-in-adults-with-her2-positive-solid-tumors-including-endometrial-colorectal-head-and-neck-cancers-sarcoma-or-her2-mutant-non-small-cell-lung-cancer/ This clinical trial focuses on treating patients with various types of solid tumors that have specific characteristics related to the HER2 gene. The study includes several types of cancer: endometrial cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, and sarcoma. These cancers must either show high levels of HER2 protein or have mutations in the HER2 gene.

The study uses a medication called zanidatamab (also known as JZP598), which is given through an intravenous infusion. This medicine is a powder that is first made into a concentrated solution before being given to patients. The maximum daily dose that can be given is 2400 milligrams, and treatment may continue for up to three years.

The main goal of this research is to determine how well zanidatamab works in treating these different types of cancer. The study will look at whether tumors respond to the treatment by shrinking or disappearing. Doctors will monitor patients regularly using scans to check how the tumors are responding to the treatment and to watch for any side effects that may occur.

]]> A study testing BNT326 and BNT327 with drug combination for safety and effectiveness in people with advanced non-small cell lung cancer https://clinicaltrials.eu/trial/a-study-testing-bnt326-and-bnt327-with-drug-combination-for-safety-and-effectiveness-in-people-with-advanced-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:08:44 +0000 https://clinicaltrials.eu/trial/a-study-testing-bnt326-and-bnt327-with-drug-combination-for-safety-and-effectiveness-in-people-with-advanced-non-small-cell-lung-cancer/ This study examines non-small cell lung cancer, which is an advanced form of lung cancer. The study will test different combinations of investigational medications. These include BNT326 and BNT327, which are experimental drugs given through infusion into a vein. Some participants may also receive standard cancer medications such as paclitaxel, carboplatin, pemetrexed, or pembrolizumab, depending on which part of the study they are in. The purpose of this study is to determine the appropriate dose of BNT326 when combined with BNT327, to assess how safe these medications are when used together, and to evaluate whether this combination treatment may help control the cancer.

The study is divided into different parts. The first part will test different dose levels of the investigational medications to find the most suitable dose for further testing. During this phase, doctors will carefully monitor participants for any side effects. The following parts of the study will test the chosen dose in larger groups of people with advanced non-small cell lung cancer to better understand how well the treatment works and how safe it is. Throughout the study, participants will receive the medications through infusion into a vein. Doctors will regularly check how the cancer responds to treatment using imaging scans and other assessments.

During the study, participants will need to provide a tissue sample from their tumor, either from a previously stored sample or from a new biopsy if needed. The study will track various aspects of participant health and treatment response, including any side effects that occur, whether the cancer shrinks or stops growing, and how long any positive effects last. Blood samples will be collected at different times to measure the levels of the investigational medications in the body and to check whether the immune system develops a response to these medications.

]]> Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations https://clinicaltrials.eu/trial/study-on-trastuzumab-deruxtecan-for-patients-with-advanced-non-small-cell-lung-cancer-with-her2-mutations/ Wed, 29 Apr 2026 14:27:27 +0000 https://clinicaltrials.eu/trial/study-on-trastuzumab-deruxtecan-for-patients-with-advanced-non-small-cell-lung-cancer-with-her2-mutations/ This clinical trial is focused on studying a type of lung cancer known as Non-Small Cell Lung Cancer (NSCLC) that cannot be surgically removed and has specific genetic changes called HER2 exon 19 or 20 mutations. The study is investigating the effectiveness and safety of a treatment called trastuzumab deruxtecan, also known by its code name DS-8201a, as the first treatment option for this type of cancer. Trastuzumab deruxtecan is a special type of medication that combines an antibody with a chemotherapy drug, designed to target and kill cancer cells more effectively.

Participants in the study will receive either trastuzumab deruxtecan or a combination of other medications, including pemetrexed, carboplatin, cisplatin, and pembrolizumab. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The purpose of the study is to compare how well trastuzumab deruxtecan works in stopping the cancer from growing or spreading compared to the other treatment options. The study will also look at the overall survival of participants and monitor any side effects they may experience.

The trial will take place over several years, with regular check-ups and assessments to monitor the participants’ health and the progress of their cancer. The study aims to provide valuable information on the best treatment options for patients with this specific type of lung cancer, potentially leading to improved outcomes and quality of life for those affected by the disease.

]]>